MIG SPRAY : preventive treatment for headaches & migraines

Overview

MIGSPRAY is an innovative preventive treatment for migraines, using a nasal spray format. This device acts through a unique osmotic mechanism and targets the proteins involved in the occurrence and development of migraine attacks.

MIG SPRAY was developed in collaboration with the European migraine research center NEURO-DOL (Inserm, CHU de Clermont-Ferrand).

Product development and research

MIGSPRAY was developed based on extensive research on the role of proteins in migraine pathogenesis. The product is specifically designed to target proteins such as CGRP, interleukins 6 and 12, or TNF α, which have been implicated in the onset of migraines. It is formulated to exert an osmotic effect, drawing these proteins away from the nasal lining into an osmotically active solution. Furthermore, the osmotic action of the spray helps clean the nasal cavity and sinuses, which can also aid in relieving the symptoms of migraines.

Mode of action

1 > Protective barrier

Migraine patients are sensitive to contaminants, allergens, odors, chemical molecules, etc. that can trigger an attack. The film created by MIG SPRAY acts as a protective barrier.

2 > Effect on migraine proteins

The osmotic action created by the film attracts CGRP and interleukins present in the nasal bloodstream. Gradually, the concentration decreases and limits the intensity of migraines.

3 > Promotes oxygenation

The osmotic action allows to drain the sinuses and to decongest the nose. This effect allows a better oxygenation of the brain and limits the occurrence of attacks.

MIGSPRAY is a promising preventive treatment for migraines. Its unique mechanism of action, combined with clinical evidence demonstrating its efficacy and safety, make it a valuable addition to the therapeutic options for migraine management. Future research can further shed light on its potential applications and benefits.

Clinical Trial

This study presents the results of a clinical trial on the clinical efficacy of a MIG SPRAY. The study included 125 patients suffering from episodic migraines, who were randomised to receive either MIG SPRAY or a placebo for a period of 12 weeks. The results showed a statistically significant reduction in the number of migraine days per month in patients treated with MIG SPRAY compared with the placebo group. In addition, no adverse effects were observed. MIG SPRAY is a safe and effective preventive treatment for migraine, which works by eliminating migraine triggers from the nasal surface and restoring the integrity of the nasal mucosa.

See full publication (PDF)

Main results

FREQUENCY

• 25% fewer migraine days per month after 2 months of treatment*
  Propranolol, the most widely prescribed prophylactic drug, reduces the frequency of attacks by an average of 30%.

OTHER PARAMETERS

• 40% reduction in crisis intensity*
  MIDAS test : Migraine disability assessment
• 71% of patients satisfied

Clinical study in children

A second clinical study in children is currently underway. This study will enable MIG SPRAY to be used from the age of 3, with an adapted dosage. Results expected in 2024